1. Medtech Insight

Symetis Adds Transfemoral TAVR Offering In Europe

The Swiss company says it is the only company other than Edwards Lifesciences and Medtronic to offer both transapical and transfemoral options for transcatheter aortic heart valve delivery.

Symetis SA announced the European launch of its Acurate neo transfemoral transcatheter aortic valve replacement system, which earned a CE mark this summer, on Sept. 11.

Acurate neo joins Symetis’ Acurate TA transapically delivered TAVR system on the European market. That makes Symetis the only company other than market-leaders Edwards Lifesciences Corp. and Medtronic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.